Age-Related Macular Degeneration and Associated Risk Factors in the Population-Based Study of Health in Pomerania (SHIP-Trend)

Lüdtke, Lisa; Jürgens, Clemens; Ittermann, Till; Völzke, Henry; Tost, Frank

doi:10.12659/msm.915493

Cited by 23 publications

(17 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study on AMD found that lipid status disorders and inflammation may play an essential role in the development of AMD in older adults [ 26 ]. Another study showed that the risk of AMD increased significantly with a higher body mass index, whereas blood pressure, HbA1c, and blood lipid-associated factors were not associated with AMD [ 27 ]. Aortic stiffness has been a risk factor for DR and peripheral neuropathy in diabetic patients [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Prevalence, Causes, and Risk Factors of Presenting Visual Impairment and Presenting Blindness in Adults Presenting to an Examination Center in Suzhou, China

Sun

Huang

Liu

et al. 2022

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. To evaluate the prevalence, causes, and risk factors of presenting visual impairment (PVI) and presenting blindness among adults in Suzhou, China. Methods. A total of 43927 subjects were included in this cross-sectional study. Each subject underwent ophthalmic examinations, including presenting visual acuity (PVA), intraocular pressure (IOP), slit-lamp examination, and fundus examination under the small pupils of each eye. Results. Using the World Health Organization (WHO) definition, the prevalence of bilateral PVI, bilateral presenting blindness, monocular PVI, and monocular presenting blindness was 1.59% (95% CI, 1.51–1.67), 0.002% (95% CI, 0.0019–0.0021), 3.87% (95% CI, 3.68–4.06), and 0.19% (95% CI, 0.18–0.20), respectively. Using the United States (US) definition, the prevalence of bilateral PVI, bilateral presenting blindness, monocular PVI, and monocular presenting blindness was 5.83% (95% CI, 5.54–6.12), 0.04% (95% CI, 0.038–0.042), 7.43% (95% CI, 7.06–7.80), and 0.45% (95% CI, 0.43–0.47), respectively. The prevalence of PVI was higher in females (WHO criteria, 2.06%, 95% CI, 1.96–2.16; US criteria, 7.27%, 95% CI, 6.91–7.63) than in males (WHO criteria, 1.2%, 95 CI%, 1.14–1.26; US criteria, 4.65%, 95% CI, 4.42–4.89). The leading cause of PVI is an uncorrected refractive error, followed by cataracts and age-related macular degeneration (AMD). Multivariate analysis proved that the prevalence of visual impairment (PVA, better eye, WHO criteria) increased significantly with older age, higher mean arterial pressure (MAP), higher globulin level, and higher fasting blood glucose (FBG). In addition, it also increased significantly with lower hemoglobin, a lower body mass index (BMI), and a lower arterial stiffness index. In this study, serum creatinine, blood urea nitrogen, uric acid, triglycerides, and the systemic immune-inflammation index (SII) showed no association with visual impairment. Conclusion. The leading causes of PVI in Suzhou were uncorrected refractive error and cataracts. The prevalence of PVI increased with females, older age, higher MAP, higher FBG, higher globulin, lower hemoglobin, lower BMI, and lower arterial stiffness index.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence, Causes, and Risk Factors of Presenting Visual Impairment and Presenting Blindness in Adults Presenting to an Examination Center in Suzhou, China

Sun

Huang

Liu

et al. 2022

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…We simulated a realistic scenario of missed intravitreal injections similar to the situation during the COVID-19 pandemic and its consequences for VA outcome. The simulated population consisted of 450,000 nAMD patients, corresponding roughly to the German nAMD population 26 , 27 . The baseline characteristics age and baseline VA were randomly drawn from the OCEAN study (Table 1 ).…”

Section: Methodsmentioning

confidence: 99%

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD

Ziemssen

Agostini

Feltgen³

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that often leads to severe and permanent vision loss. Early initiation of anti-vascular endothelial growth factor (anti-VEGF) therapy has been shown to preserve vision in nAMD patients. Concurrently, treatment outcomes in real-world are inferior to those reported in clinical trials. The most likely reasons observed are fewer treatment-intensity in routine clinical practice than in clinical trials. The other possibility could be the delay in starting treatment and the re-treatment interval. Although a negative impact of aforementioned parameters seems obvious, quantitative impact measures remain elusive in a real-world setting due to a lack of an ‘optimal treatment’ control group. To overcome this shortcoming, we developed, validated, and applied a model to assess and quantify the impact of anti-VEGF administration variables on visual acuity development in a prospective nAMD patient cohort. The model was further applied to probe the impact of the COVID-19 pandemic on visual progressions in nAMD patients. The presented model paves the way to systematically explore and evaluate realistic interventions in the current treatment paradigm, that can be adopted in routine clinical care.

show abstract

“…SHIP is a population-based study that was conducted in North-Eastern Germany. Between 2008 and 2012 (N = 4,420), the SHIP-TREND-0 was performed, collecting primary data from local registries [17,21,22]. Details of the measurements performed in the SHIP-TREND-0 study were published [17,23,24].…”

Section: Replication Studymentioning

confidence: 99%

Identification of candidate metabolite biomarkers for metabolic syndrome and its five components in population-based human cohorts

Shi

Han

Klier

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Metabolic syndrome (MetS) consists of risk factors (abdominal obesity, hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL–C), hypertension, hyperglycemia) for cardiovascular disease and type 2 diabetes. Here, we aim to identify candidate metabolite biomarkers of MetS and its risk factors to better understand the complex interplay of underlying signaling pathways. Methods We quantified serum samples of the KORA F4 study participants (N = 2,815) and analyzed 121 metabolites. Using multiple regression models adjusted for clinical and lifestyle covariates, we examined metabolites that have a Bonferroni significant MetS association, and replicated them in the SHIP-TREND-0 study (N = 988), and further analyzed for each of the five components of MetS. Database-based networks of the identified metabolites with interacting enzymes were also constructed. Results We identified and replicated 56 MetS-specific metabolites: 13 positively associated (e.g., Val, Leu/Ile, Phe and Tyr, sum of hexoses, 2 carnitines, and 6 lipids), and 43 negatively associated (e.g., Gly, Ser, and 40 lipids). Furthermore, most (89%) and least (23%) of the MetS-specific metabolites were separately associated with low HDL–C and hypertension among the components. One lipid, lysoPC a C18:2, was negatively associated with MetS and all of the five components, indicating patients with MetS and each of the risk factors had lowered concentrations of lysoPC a C18:2 compared to corresponding healthy controls. Our metabolic networks clarified our observations by revealing impaired catabolisms of branched-chain and aromatic amino acids, as well as higher rates of Gly catabolism. Conclusion Our identified candidate metabolite biomarkers are associated with the pathophysiology of MetS and its risk factors and could help develop therapeutic strategies to prevent type 2 diabetes and cardiovascular disease. For example, higher levels of lysoPC a C18:2 may provide protection against MetS and its five risk components. More in-depth studies are necessary to determine the mechanism of key metabolites in the MetS pathophysiology.

show abstract

Age-Related Macular Degeneration and Associated Risk Factors in the Population-Based Study of Health in Pomerania (SHIP-Trend)

Cited by 23 publications

References 27 publications

Prevalence, Causes, and Risk Factors of Presenting Visual Impairment and Presenting Blindness in Adults Presenting to an Examination Center in Suzhou, China

Prevalence, Causes, and Risk Factors of Presenting Visual Impairment and Presenting Blindness in Adults Presenting to an Examination Center in Suzhou, China

A model to quantify the influence of treatment patterns and optimize outcomes in nAMD

Identification of candidate metabolite biomarkers for metabolic syndrome and its five components in population-based human cohorts

Contact Info

Product

Resources

About